# US 2025/0319132 A1 · Methods and compositions for improving the immune response against viral pathogens

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0319132 A1
- Document ID: US20250319132A1
- Status: Published application
- Kind: A1
- Application number: 19/180,751
- Filed: 2025-04-16
- Published: 2025-10-16
- Earliest claimed: 2024-04-16
- Applicants: Mirror Biologics, Inc.
- Inventors: Michael Har-Noy
- Web page: https://patentgrep.com/patent/US20250319132A1

## CPC

- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/32: T-cell receptors [TCR]
- A61K 40/418: {Antigens related to induction of tolerance to non-self}
- A61K 40/421: {Immunoglobulin superfamily}
- A61K 40/50: characterised by the use of allogeneic cells
- A61P 37/04: Immunostimulants
- C07K 14/525: Tumour necrosis factor [TNF]
- C07K 14/535: Granulocyte CSF; Granulocyte-macrophage CSF
- C07K 14/57: IFN-gamma
- C07K 14/70575: {NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154 (NGF C07K14/48, TNF C07K14/525)}
- A61K 2039/572: {cytotoxic response}
- A61K 2039/58: {raising an immune response against a target which is not the antigen used for immunisation}
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- C12N 2770/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Immunotherapy regimens against a viral pathogen in individuals are disclosed. The immunotherapy regimen is a universal vaccine that is administered intradermally. Multiple intradermal doses of the universal vaccine are administered to elderly individuals to prime the individual's immune system for an effective response against a viral pathogen.

## Claims

### Claim 1

A method of improving the immune response in an individual against a viral pathogen comprising:
administering allogeneic living immune cells where at least a portion are T-cells wherein the T-cells comprise effector/memory T-cells of a Th1 phenotype that produces IFN-γ and not IL-4.

### Claim 2 (depends on 1)

The method of claim 1 wherein the allogeneic living immune cells are administered in at least three intradermal doses.

### Claim 3 (depends on 1)

The method of claim 1 wherein the effector/memory T-cells express CD45RO+ and CD62LLo.

### Claim 4 (depends on 1)

The method of claim 1 wherein the effector/memory Th1 cells are activated at formulation or introduction to the individual.

### Claim 5 (depends on 4)

The method of claim 4 wherein the activation of the T-cells comprises cross-linking of CD3 and CD28 surface molecules on the T-cells.

### Claim 6 (depends on 1)

The method of claim 1 wherein the T-cells cells can express CD40L upon being activated and produce inflammatory cytokines.

### Claim 7 (depends on 6)

The method of claim 6 wherein the inflammatory cytokines comprise IFN-γ, GM-CSF, or TNF-α or combinations thereof.

### Claim 8 (depends on 1)

The method of claim 1 wherein at least a portion of the effector/memory T-cells are derived from naïve CD4+ T-cells from a donor other than the individual.

### Claim 9 (depends on 2)

The method of claim 2 wherein each of the doses of intradermal doses are administered at an interval of about 3 to 4 days.

### Claim 10 (depends on 1)

The method of claim 1, wherein the invading pathogen is a virus.

### Claim 11 (depends on 1)

The method of claim 1, wherein the invading pathogen is a coronavirus, RSV, Influenza A or Influenza B.

### Claim 12 (depends on 1)

The method of claim 1, wherein the individual is over the age of 60.

### Claim 13 (depends on 1)

The method of claim 1, wherein administration of the allogeneic living immune cells increases the level of IFN-gamma in the individual and/or the Th1 response after pathogen infection.

### Claim 14 (depends on 1)

The method of claim 1, wherein the Th1/Th2 balance shifts toward Th1.

### Claim 15 (depends on 2)

The method of claim 2, wherein a fourth, a fifth, or more intradermal doses are administered to the individual.

### Claim 16 (depends on 1)

The method of claim 1 wherein the allogeneic living immune cells are administered with selected viral antigens.

### Claim 17

A method of modulating the immune response in an individual at least 60 years of age comprising administering allogeneic living immune cells where at least a portion are T-cells wherein the T-cells comprise effector/memory T-cells of a Th1 phenotype that increases the Th1/Th2 ratio.

### Claim 18 (depends on 17)

The method of claim 17 wherein the allogeneic living immune cells are administered in at least three intradermal doses.

### Claim 19 (depends on 17)

The method of claim 17 wherein the effector/memory T-cells express CD45RO+ and CD62LLo.

### Claim 20 (depends on 17)

The method of claim 17 wherein the effector/memory Th1 cells are activated at formulation or introduction to the individual.

### Claim 21 (depends on 20)

The method of claim 20 wherein the activation of the T-cells comprises cross-linking of CD3 and CD28 surface molecules on the T-cells.

### Claim 22 (depends on 17)

The method of claim 17 wherein the T-cells cells can express CD40L upon being activated and produce inflammatory cytokines.

### Claim 23 (depends on 22)

The method of claim 22 wherein the inflammatory cytokines comprise IFN-γ, GM-CSF, or TNF-α or combinations thereof.

### Claim 24 (depends on 17)

The method of claim 17 wherein at least a portion of the effector/memory T-cells are derived from naïve CD4+ T-cells from a donor other than the individual.

### Claim 25 (depends on 17)

The method of claim 17 wherein each of the doses of intradermal doses are administered at an interval of about 3 to 4 days.

### Claim 26 (depends on 17)

The method of claim 17, wherein administration of the allogeneic living immune cells increases the level of IFN-gamma in the individual and/or the Th1 response after pathogen infection.

### Claim 27 (depends on 18)

The method of claim 18, wherein a fourth, a fifth, or more intradermal doses are administered to the individual.

### Claim 28 (depends on 17)

The method of claim 17 wherein the allogeneic living immune cells are administered with selected viral antigens.

### Claim 29

A method of increasing vaccine responsiveness in an individual fully vaccinated against at least one viral infection without additional doses of a vaccine for the at least one viral infection and comprising administering one or more doses of a vaccine composition to the fully vaccinated individual, the vaccine composition comprising allogeneic effector/memory Th-1 cells derived from a deliberately HLA-mismatched donor to the individual.

### Claim 30 (depends on 29)

The method of claim 29 and further comprising administering at least three doses of the vaccine composition.
